Radiation jolt may wake up fading immunotherapy
NCT ID NCT06363773
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether precise, high-dose radiation (stereotactic radiotherapy) can restore the effectiveness of anti-PD1 immunotherapy in patients with metastatic solid tumors. Participants are those who initially responded well to immunotherapy for at least 6 months but then saw their cancer progress. The radiation is given in three short sessions to one tumor, with the hope that it triggers an 'abscopal effect'—shrinking not only the treated tumor but also other distant metastases. The study enrolls 35 patients and measures tumor response at 3 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
stereotactic radiotherapy
What this could lead to
If successful, this approach could offer a way to re-sensitize tumors to immunotherapy, potentially extending disease control without new drugs.
What could go wrong
This is a very small, early pilot study (35 patients) with no control group. The abscopal effect is rare and unpredictable, so results may not be generalizable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Clinical
RECRUITINGSoyaux, Charente, 16800, France